EGS21, Enzo’s Orally Administered Glucosylceramide Formulation, Named Among Top 10 Inflammatory/Autoimmune Projects to Watch at Meeting
NEW YORK, NY, November 13, 2009 – Enzo Biochem Inc. (NYSE:ENZ) announced today that David Goldberg, Vice President, Corporate Development, will speak on the Company’s extensive oral immune regulation platform at the Windhover TA Partnerships 2009 conference in Boston, MA, on Wednesday, November 18, 2009, where Enzo’s EGS21, an orally administered beta glucosylceramide formulation, now undergoing clinical study, was named one of this year’s “top 10 inflammatory/autoimmune projects to watch.”
“This is a welcome recognition by a leading industry information organization,” said Mr. Goldberg. “EGS21 is one of several formulations derived from Enzo’s pioneering therapeutic platforms utilizing oral immune regulation for immune mediated diseases. Our Enzo Therapeutics subsidiary has long viewed oral immune regulation as an exciting and promising platform, and it is one that we continue to pursue through studies involving treatment candidates for unmet medical needs.”
Among the other projects based on this platform, Mr. Goldberg said, is Alequel™, an individualized therapy for treatment of Crohn’s disease, and Optiquel™, an oral, novel peptide for autoimmune uveitis, currently involved in a proof of concept trial undertaken in conjunction with the National Eye Institute.
In a report at the recent Liver Conference on clinical studies involving EGS21, data was presented showing that oral administration of EGS21 appears to be safe and biologically active in patients with insulin resistance and NASH (non-alcoholic steatohepatitis), a nonalcoholic fatty liver disease that is the most common form of chronic liver disease in the Western world.
The TA Partnership 2009 conference is sponsored by Windhover Information Inc., part of Elsevier, the world’s leading publisher of science, technical and health information. For 20 years Windhover Information has been a major provider of analysis and commentary on health care business strategy, industry deal making, marketplace trends, and the world of medical start-ups.
About Enzo
Enzo Biochem is engaged in the research, development, manufacture and licensing of innovative health care products and technologies based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. Enzo’s Life Sciences division develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research among others. Its catalog of over 40,000 products serves the molecular biology, drug discovery and pathology research markets. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary immune regulation medicines for uveitis and Crohn's disease and conducts pre-clinical research on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. Enzo’s Clinical Labs division provides routine and esoteric reference laboratory services for physicians in the New York Metropolitan and New Jersey areas. Underpinning the Company’s technology and operations is an extensive intellectual property estate in which Enzo owns or licenses over 230 patents worldwide, and has pending applications for over 200 more. For more information visit the Company’s website www.enzo.com.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
Contact:
For: Enzo Biochem, Inc.
Steven Anreder, 212-532-3232 Or Michael Wachs, CEOcast, Inc., 212-732-4300